The interplay of NAD+, hyperuricemia, and renal damage: A scientific review
Pathology - Research and Practice · 2025
DOI: 10.1016/j.prp.2025.156256 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2025. Verfasst von Laura Gabriela Sánchez-Lozada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Deptartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico. Electronic address: laura.sanchez…. Hauptthemen laut MEDLINE: Hyperuricemia, NAD, Renal Insufficiency, Chronic, Kidney. Die Arbeit nennt 91 Literaturangaben. Gefördert von: Secretaria de Ciencia Humanidades Tecnologia e Innovacion.
Abstract (Originalsprache)
Identifying potential mechanisms by which hyperuricemia might cause kidney diseases is important, as it may help identify new therapies. Nicotinamide adenine dinucleotide (NAD+) is a coenzyme involved in hundreds of metabolic reactions, including bioenergetics, DNA repair, and gene expression. Hyperuricemia (HU) is a common metabolic disorder associated with the development of chronic kidney disease (CKD), beyond its well-established links to gout and kidney stones. Here, we review the complex relationship between NAD+ levels, HU, and renal damage. Uric acid (UA) crystal deposition induces a local inflammatory response linked to Toll-like receptor and inflammasome activation, while soluble UA drives mitochondrial and endothelial dysfunction, activation of the renin-angiotensin system, inflammation, and epithelial and endothelial-to-mesenchymal transition. Here we discuss how oxidative stress, mitochondrial dysfunction, and inflammation from HU can indirectly deplete intracellular NAD+ by increasing the activity of NAD+-consuming enzymes. Given NAD+´s critical role in kidney health, therapeutically increasing NAD+ levels through precursor supplementation (e.g., nicotinamide, nicotinamide riboside, nicotinamide mononucleotide) or inhibiting NAD+ consuming enzymes shows promise for preventing or treating HU-associated kidney damage. We recommend clinical trials to determine if increasing NAD+ levels can improve the management of HU-induced kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Deptartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico. Electronic address: laura.sanchez@cardiologia.org.mx.
- Deptartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico.
- Deptartment of Cardio-Renal Physiopathology, Instituto Nacional de Cardiologia Ignacio Chávez, Mexico City, Mexico; Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutricion Sal…
- Division of Medicine, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.
Förderung
- Secretaria de Ciencia Humanidades Tecnologia e Innovacion
Zitieren
APA
Sánchez-Lozada, L. G., García-Arroyo, F., Gonzaga-Sánchez, G., Aparicio-Trejo, O. E., Cuevas, B., Reyes-Leo, M., Rodríguez-Iturbe, B., & Johnson, R. J. (2025). The interplay of NAD+, hyperuricemia, and renal damage: A scientific review. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2025.156256
Vancouver
Sánchez-Lozada LG, García-Arroyo F, Gonzaga-Sánchez G, Aparicio-Trejo OE, Cuevas B, Reyes-Leo M, et al. The interplay of NAD+, hyperuricemia, and renal damage: A scientific review. Pathology - Research and Practice. 2025. doi:10.1016/j.prp.2025.156256
BibTeX
@article{SnchezLozada2025,
author = {Sánchez-Lozada, Laura Gabriela and García-Arroyo, Fernando and Gonzaga-Sánchez, Guillermo and Aparicio-Trejo, Omar Emiliano and Cuevas, Belén and Reyes-Leo, Marlene and Rodríguez-Iturbe, Bernardo and Johnson, Richard J},
title = {The interplay of NAD+, hyperuricemia, and renal damage: A scientific review},
journal = {Pathology - Research and Practice},
year = {2025},
doi = {10.1016/j.prp.2025.156256}
}
EUVIMED